Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial.
Saved in:
| Title: | Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial. |
|---|---|
| Authors: | Weiss, Anne1,2 (AUTHOR), Delavenne, Emilie1 (AUTHOR), Matias, Carina1 (AUTHOR), Lagler, Heimo3 (AUTHOR), Simon, Daniel1 (AUTHOR), Li, Ping1 (AUTHOR), Hansen, Jon U.4 (AUTHOR), dos Santos, Teresa Pires5 (AUTHOR), Jana, Bimal5 (AUTHOR), Priemel, Petra6 (AUTHOR), Bangert, Christine7 (AUTHOR), Bauer, Martin8 (AUTHOR), Eberl, Sabine8 (AUTHOR), Nussbaumer‐Pröll, Alina8 (AUTHOR), Anne Österreicher, Zoe8 (AUTHOR), Matzneller, Peter8 (AUTHOR), Quint, Tamara7 (AUTHOR), Weber, Maria8 (AUTHOR), Nielsen, Hanne Mørck6 (AUTHOR), Rades, Thomas6 (AUTHOR) |
| Source: | Clinical & Translational Medicine. May2022, Vol. 12 Issue 5, p1-21. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20011326 |
|---|---|
| DOI: | 10.1002/ctm2.790 |
